GlassScriptPhysician profile
Muthena A Maklad
NPI 1609118959
$10,006.47
in general payments reported to CMS, 2019-2025
30 companies · $2,198 in 2025
The $2,198 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $114 · 2021: $1,242 · 2022: $1,492 · 2023: $1,947 · 2024: $1,891 · 2025: $2,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,952 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,952.07 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,727.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,684.41 | 2020-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $983.39 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Boston Scientific Corporation | $877.50 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $771.00 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $464.64 | 2021-2025 | |
| Cook Medical LLC | $294.89 | 2019 | |
| Celgene Corporation | $257.03 | 2021-2023 | Zeposia |
| Genzyme Corporation | $249.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $226.98 | 2019-2024 | Dificid |
| Lucid Diagnostics INC. | $180.92 | 2022 | |
| Pfizer INC. | $168.41 | 2024-2025 | |
| Qol Medical, LLC | $136.59 | 2020-2023 | Sucraid |
| Braintree Laboratories, INC. | $110.03 | 2021-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $109.90 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $107.72 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $105.98 | 2024-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $104.78 | 2020-2022 | |
| Redhill Biopharma INC. | $70.23 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Celltrion USA INC. | $63.41 | 2024-2025 | Vegzelma |
| Orphalan INC | $53.89 | 2025 | Cuvrior |
| Lilly USA, LLC | $48.81 | 2023-2025 | Omvoh |
| Intra-Sana Laboratories | $41.65 | 2021 | |
| Nestle Healthcare Nutrition INC. | $34.66 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $33.09 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $29.12 | 2025 | Voquezna |
| Organon LLC | $19.68 | 2023 | Hadlima |
| Ardelyx, INC. | $17.43 | 2022 | |
| Novo Nordisk INC | $16.95 | 2025 | Wegovy |
| Exact Sciences Corporation | $15.90 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muthena Maklad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.